XML 42 R9.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Operations | 6 Months Ended
--- | ---
Jun. 30, 2013
Operations [Abstract] |
Operations | Note 2 - Operations The Company's vaccine candidates currently under development will require significant additional research and development efforts that include extensive pre-clinical and clinical testing, and regulatory approval prior to commercial use. The Company's research and development efforts may not be successful and any potential vaccine candidates may not prove to be safe and effective during clinical development. Even if developed, these vaccine candidates may not receive regulatory approval or be successfully introduced and marketed at prices that would permit the Company to operate profitably. The commercial launch of any vaccine is subject to significant risks including, but not limited to, manufacturing scale-up and market acceptance. As a clinical-stage biopharmaceutical company, the Company has primarily funded its operations from proceeds through the sale of its common stock in equity offerings and under its At Market Issuance Sales Agreements and revenue under its contract with the Department of Health and Human Services, Biomedical Advanced Research and Development Authority ("HHS BARDA"). Management regularly reviews the Company's cash and cash equivalents and investments against its operating budget to ensure the Company will have sufficient working capital, and will continue to draw upon such available sources of capital to meet its operating needs.

X
- Details
Name: | nvax_OperationsAbstract
Namespace Prefix: | nvax_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Operations Disclosure [Text Block] + References No definition available. + Details
Name: | nvax_OperationsDisclosureTextBlock
Namespace Prefix: | nvax_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration